Drug
Daunorubicin clinical trials
Also written Cerubidine, Daunomycin, RP-13057 and FI-6339.
Includes 9 studies of Daunorubicin citrate.
- studies test it
- 110
- open now
- 21
- in phase 3
- 36
- first study started
- 1993
Keep track of what changes. Save the Daunorubicin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Other names
Combined with it in one product
Studies by the year they started
109 studies that test it; most in 2008 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1994 | 1 |
| 1996 | 4 |
| 1997 | 1 |
| 1998 | 3 |
| 1999 | 6 |
| 2000 | 7 |
| 2001 | 4 |
| 2002 | 6 |
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 8 |
| 2009 | 1 |
| 2010 | 4 |
| 2012 | 3 |
| 2013 | 4 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 2 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 28
- Phase 2
- 47
- Phase 3
- 36
- Phase 4
- 5
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 102
National Cancer Institute (NCI) (15) · Children's Oncology Group (13) · St. Jude Children's Research Hospital (11) · Institute of Hematology & Blood Diseases Hospital, China (5) · SWOG Cancer Research Network (4) · Memorial Sloan Kettering Cancer Center (2) · Children's Cancer Group, China (2) · Wake Forest University Health Sciences (2)
Often tested with
Tested in the same studies.
Cytarabine (83) · Methotrexate (33) · Cyclophosphamide (33) · Etoposide (32) · Mercaptopurine (31) · Vincristine (30) · Dexamethasone (29) · Thioguanine (23)
Studies
Open first, then newest update. How each study uses Daunorubicin is read from its arms, and is right about nine times in ten.
Testing it · 110
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Daunorubicin
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Daunorubicin Hydrochloride
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554393Written as Daunorubicin Hydrochloride
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingPhase 3Kura Oncology, Inc.NCT07007312Written as Daunorubicin
- Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07862517Written as Daunorubicin
- A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaRecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07255872Written as Daunorubicin
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as Daunorubicin (BAML-16-001-S1)
- A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07754799Written as Daunorubicin
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseRecruitingPhase 1National Cancer Institute (NCI)NCT05886049Written as Daunorubicin
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as Daunorubicin
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as Daunorubicin/ Idarubicin /Mitoxantrone
- Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and LymphomaRecruitingPhase 2St. Jude Children's Research HospitalNCT06533748Written as Daunorubicin
- Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/LymphomaRecruitingPhase 4St. Jude Children's Research HospitalNCT06289673Written as Daunorubicin
- Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651163Written as Lisaftoclax+daunorubicin+cytarabine
- Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651176Written as Lisaftoclax+daunorubicin+cytarabine
- Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).RecruitingPhase 4Fujian Medical University Union HospitalNCT07561892Written as daunomycin/Idarubicin+ Silybinin
- Revumenib in Combination With 7+3 + Midostaurin in AMLRecruitingPhase 1Richard Stone, MDNCT06313437Written as Daunorubicin
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)RecruitingPhase 3Children's Cancer Group, ChinaNCT05681260Written as Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingPhase 1Kura Oncology, Inc.NCT05735184Written as Daunorubicin
- Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDSRecruitingPhase 1Montefiore Medical CenterNCT05342584Written as Daunorubicin
See all 110 studies that test Daunorubicin →
Given in every arm · 97 — Daunorubicin is usual care beside what is tested
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Daunorubicin
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Daunorubicin
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06917911Written as Daunorubicin Hydrochloride
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as Daunorubicin Hydrochloride
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07636564Written as Daunorubicin Hydrochloride
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06918431Written as Daunorubicin Hydrochloride
- Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AMLRecruitingPhase 2Beijing 302 HospitalNCT07078591Written as Daunorubicin
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3Children's Oncology GroupNCT04293562Written as Daunorubicin Hydrochloride
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2St. Jude Children's Research HospitalNCT05955261Written as Daunorubicin Hydrochloride
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3Children's Oncology GroupNCT03959085Written as Daunorubicin Hydrochloride
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingPhase 2St. Jude Children's Research HospitalNCT06390319Written as Daunorubicin
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1RecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT06744504Written as daunorubicin
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Not yet recruitingPhase 2/3Children's Oncology GroupNCT07072585Written as Daunorubicin Hydrochloride
- Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid LeukemiaRecruitingPhase 1OHSU Knight Cancer InstituteNCT04659616Written as Daunorubicin
- Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AMLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06635681Written as Daunorubicin
- International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic LymphomaRecruitingPhase 3University Hospital MuensterNCT04043494Written as Daunorubicin
- CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsRecruitingPhase 2Princess Maxima Center for Pediatric OncologyNCT06262438Written as Daunorubicin
- Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05660473Written as Daunorubicin
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017RecruitingPhase 3Martin SchrappeNCT03643276Written as Daunorubicin
- Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 3Shanxi Bethune HospitalNCT05726110Written as Daunorubicin
Showing 20 of 97.
As the comparator · 28 — what is tested is compared with Daunorubicin
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingPhase 2OHSU Knight Cancer InstituteNCT07228273Written as Daunorubicin
- VA vs DA for Newly Diagnosed Hig-risk AMLRecruitingPhase 2/3The First Affiliated Hospital of Soochow UniversityNCT05939180Written as Daunorubicin
- Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06529250Written as Daunorubicin+Cytarabine
- Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRRecruitingPhase 2/3University Hospital, AngersNCT02416388Written as Daunorubicin
- Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 MutationsNot yet recruitingPhase 2Shen yangNCT07664839Written as Cytarabine plus Daunorubicin
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07407140Written as Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib
- Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsRecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07132684Written as Daunorubicin/Idarubicin
- Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALLRecruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT06361329Written as Daunorubicin
- Optimum Induction Therapy of Low-risk APLRecruitingNot applicablePeking University People's HospitalNCT05832320Written as Daunorubicin
- Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)RecruitingNot applicableFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT03390387Written as Daunorubicin
- Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia PatientsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04817241Written as Daunorubicin
- Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLCompletedPhase 2GWT-TUD GmbHNCT04061239Written as Daunorubicin
- Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedPhase 3AmgenNCT02393859Written as Daunorubicin
- HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AMLActive, not recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06744556Written as daunorubicin
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedPhase 3Goethe UniversityNCT02881086Written as Daunorubicin (DNR)
- Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML PatientsTerminatedPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05361057Written as Venetoclax, daunorubicin, cytarabine
- Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse GeneticsActive, not recruitingPhase 3University of UlmNCT03897127Written as Daunorubicin
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedPhase 3Gilead SciencesNCT04778397Written as Daunorubicin
- Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 3ECOG-ACRIN Cancer Research GroupNCT02085408Written as Daunorubicin
- A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid LeukemiaTerminatedPhase 1PfizerNCT02954653Written as Daunorubicin
Showing 20 of 28.
Codes
What other systems call Daunorubicin · ClinicalTrials.gg INT007300
- MeSH (NLM) D003630DaunorubicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ZS7284E0ZPDAUNORUBICINConfirmed FDA, NLM, Wikidata
- RxNorm 3109Confirmed FDA, Wikidata
- Wikidata Q411659daunorubicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62091DaunorubicinOne source FDA
- DrugBank DB00694One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003630 | Daunorubicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ZS7284E0ZP | DAUNORUBICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3109 | — | Confirmed FDA, Wikidata |
| Wikidata | Q411659 | daunorubicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62091 | Daunorubicin | One source FDA |
| DrugBank | DB00694 | — | One source Wikidata |
Also registered as daunorubicin hydrochloride (UNII UD984I04LZ · RxNorm 81992).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.